Sign In
Buy CLSN
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
08:00am, Monday, 15'th Aug 2022
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
12:30pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, anno
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
09:30am, Monday, 08'th Aug 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announ
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
08:30am, Monday, 08'th Aug 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, annou
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
12:35pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
09:30am, Tuesday, 19'th Jul 2022
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
08:35am, Tuesday, 19'th Jul 2022
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced th
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
08:30am, Tuesday, 19'th Jul 2022
Michael H. Tardugno appointed Executive Chairman of the Board
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
12:30pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit
Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript
03:26pm, Monday, 16'th May 2022
Celsion Corporation (NASDAQ:CLSN ) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Office
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
08:00am, Monday, 16'th May 2022
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
08:30am, Tuesday, 10'th May 2022
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
12:30pm, Monday, 09'th May 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, annou
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
08:30am, Monday, 09'th May 2022
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announ
